Brokerages Set DaVita Inc. (NYSE:DVA) Price Target at $155.80

DaVita Inc. (NYSE:DVA) has been given a consensus recommendation of “Hold” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $155.80.

Several analysts have recently weighed in on the company. TD Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Barclays increased their price objective on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Finally, Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DVA. Elevation Wealth Partners LLC grew its holdings in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after buying an additional 165 shares during the last quarter. Caitlin John LLC purchased a new stake in DaVita during the 4th quarter valued at approximately $34,000. Sankala Group LLC acquired a new stake in DaVita during the 4th quarter worth approximately $39,000. Canada Pension Plan Investment Board acquired a new stake in DaVita during the 2nd quarter worth approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new position in shares of DaVita in the 4th quarter valued at approximately $45,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Trading Up 0.0%

Shares of DaVita stock opened at $154.43 on Friday. The company has a fifty day simple moving average of $140.32 and a 200-day simple moving average of $128.12. The stock has a market cap of $10.32 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 0.54 and a beta of 0.93. DaVita has a 12-month low of $101.00 and a 12-month high of $159.42.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same period in the previous year, the company earned $2.24 earnings per share. DaVita’s quarterly revenue was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, analysts forecast that DaVita will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.